FDA Warns Companies Against False and Misleading Drug Ads

Regulators sent dozens of letters to companies such as Eli Lilly and Hims and Hers.

The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023.Madalina Vasiliu/The Epoch Times

Federal regulators sent dozens of letters to companies in September warning them that their advertisements for drugs are misleading and could lead to repercussions unless fixed.

The Food and Drug Administration on Sept. 16 released 65 letters it sent on Sept. 9 to companies, including Eli Lilly and Novo Nordisk. President Donald Trump signed a memorandum that day directing officials to enforce existing rules surrounding direct-to-consumer advertising for drugs.